Date: 2013-03-01
Type of information: Company acquisition
Acquired company: Encap Drug Delivery (UK)
Acquiring company: Capsugel (USA)
Amount: undisclosed
Terms: Capsugel has acquired Encap Drug Delivery. Based in Scotland, Encap’s focus on liquid and semi-solid encapsulation-based product development, and clinical and commercial manufacturing for the pharmaceutical industry. These capabilities complement Capsugel’s recently-established Dosage Form Solutions (DFS) business unit which develops and manufactures innovative products for the healthcare industry.
Details: Encap operates an FDA and MHRA inspected pharmaceutical product development and manufacturing site, is equipped to handle high potency active ingredients, and has established a clinical fast-track program that can speed the process from lab to clinic. Additionally, Encap’s proprietary targeted release technologies (DuoCap™ and ENCODE®) and abuse deterrence technologies (Abusolve®) will add to Capsugel’s growing suite of offerings in these areas.
Capsugel DFS’s lipid-based technology platform currently includes proprietary Licaps® liquid-filled capsules, softgels, solid-lipid pellets, and a lipid formulation software system aimed at accelerating lipid-based product development for customers. The business unit’s emerging targeted release technology platform includes specialized capsules that enable different types and levels of controlled release delivery.
Related: drug services
drug delivery
